menu

Improving HPV Immunization Among US Adults: Implementing Vaccine Recommendations

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Improving HPV Immunization Among US Adults: Implementing Vaccine Recommendations

0.50 credits
30 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
  • Overview

    Human papillomavirus (HPV) is a common sexually transmitted infection spread through intimate skin-to-skin contact. Recommendations for the prevention of HPV have been updated since the initial HPV vaccine was first licensed in the US in 2006. Although immunization is routinely recommended in early adolescence, it is now also available for adults age 27-45 years, and certain patients may benefit from receiving it. However, there are limited resources available to help discuss HPV vaccination with adult patients. This activity is based on the latest CDC recommendations for vaccinating US adults against HPV and includes practical implementation strategies for shared clinical decision-making. 

  • Disclosure of Conflicts of Interest

    • Marla Dalton (NFID Staff) owned stock from Merck & Co., Inc.
    • Margot Savoy (Speaker) served as an author for Merck & Co., Inc.

    All of the relevant financial relationships listed for these individuals have been mitigated

    All other individuals in a position to control the content of this activity have no relevant financial relationships with ineligible companies to disclose

  • Target Audience

    Healthcare professionals (physicians, pharmacists, nurses, nurse practitioners, physician assistants, and other public health professionals) working in a variety of practice settings with adult patients

  • Learning Objectives

    At the conclusion of the activity, participants will be able to:

    • Describe current recommendations for human papillomavirus (HPV) vaccination in US adults
    • Implement communication strategies to help identify and discuss the benefits of HPV vaccination with those adults most likely to benefit
  • Accreditation and Credit Designation Statements

    The National Foundation for Infectious Diseases (NFID) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    NFID designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an unrestricted educational grant from Merck & Co., Inc.

    NFID policies restrict funders from controlling program content. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
  • Overview

    Human papillomavirus (HPV) is a common sexually transmitted infection spread through intimate skin-to-skin contact. Recommendations for the prevention of HPV have been updated since the initial HPV vaccine was first licensed in the US in 2006. Although immunization is routinely recommended in early adolescence, it is now also available for adults age 27-45 years, and certain patients may benefit from receiving it. However, there are limited resources available to help discuss HPV vaccination with adult patients. This activity is based on the latest CDC recommendations for vaccinating US adults against HPV and includes practical implementation strategies for shared clinical decision-making. 

  • Disclosure of Conflicts of Interest

    • Marla Dalton (NFID Staff) owned stock from Merck & Co., Inc.
    • Margot Savoy (Speaker) served as an author for Merck & Co., Inc.

    All of the relevant financial relationships listed for these individuals have been mitigated

    All other individuals in a position to control the content of this activity have no relevant financial relationships with ineligible companies to disclose

  • Target Audience

    Healthcare professionals (physicians, pharmacists, nurses, nurse practitioners, physician assistants, and other public health professionals) working in a variety of practice settings with adult patients

  • Learning Objectives

    At the conclusion of the activity, participants will be able to:

    • Describe current recommendations for human papillomavirus (HPV) vaccination in US adults
    • Implement communication strategies to help identify and discuss the benefits of HPV vaccination with those adults most likely to benefit
  • Accreditation and Credit Designation Statements

    The National Foundation for Infectious Diseases (NFID) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    NFID designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by an unrestricted educational grant from Merck & Co., Inc.

    NFID policies restrict funders from controlling program content. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule20 Jun 2024